Last updated 25 August 2026 · Originally published 13 June 2020
CBD is often said to work on serotonin, the brain chemical most people associate with mood, and that claim is the basis for much of what is written about CBD, anxiety and depression. The claim has a real origin. What it does not have, yet, is much support from studies in people, and the gap between the two is worth understanding before you buy CBD for your mood.
Where the idea comes from
Serotonin does not act on its own. It works by attaching to receptors on nerve cells, and there are more than a dozen kinds. One of them, called 5-HT1A, is a target of several anxiety and antidepressant drugs. In 2005, a laboratory study found that CBD could attach to this receptor and switch it on. That experiment became the starting point for the direct-receptor story.
Two details matter. First, CBD’s grip on the receptor is weak. It took concentrations far higher than anything measured in the blood of people taking CBD by mouth, even at the several hundred milligrams a day used in clinical trials, let alone the 10 to 25 mg in a retail serving. Second, it was a test-tube finding. Whether the same thing happens in a living brain, at doses people take, is a different question.
The strongest support for 5-HT1A involvement comes from rats. In several experiments, CBD reduced anxiety-like behaviour, and giving the rats a drug that blocks 5-HT1A made that effect disappear. That is reasonable evidence that the receptor contributes to CBD’s effects in rats. It does not establish that CBD directly activates the receptor in people.
What the human trials show
The human evidence for CBD’s effects on mood does not test the serotonin idea directly. It asks a simpler question: does CBD help, whatever it is doing? And the answer depends a great deal on which condition you mean.
For anxiety, there is a real signal. Several small trials found that a single large dose, usually 300 to 600 mg, took the edge off anxiety before a stressful task like public speaking, and a 2024 industry-funded trial of 178 people reported substantial improvement after 12 weeks of a nanodispersible CBD formulation delivering 300 to 600 mg a day. The formulation, dose and trial design make that result difficult to transfer to ordinary retail CBD — we go through the anxiety evidence separately, including its limits. None of those trials measured serotonin, so they can neither confirm nor rule out that 5-HT1A is the reason.
For depression, the picture is thinner and mostly negative. A 2023 trial of 35 people with bipolar depression added CBD or placebo to their usual treatment for eight weeks; both groups improved, and CBD was no better. A small 2026 crossover trial in people with primary brain tumours gave 600 mg a day for three weeks and found no benefit for anxiety or depressive symptoms; scores generally favoured placebo. The trial ended early after enrolling only 20 people, and side effects were comparable between CBD and placebo. We could not find a placebo-controlled trial in which CBD improved depression as its main outcome. That does not prove CBD has no effect on serotonin. It means the receptor theory has not translated into demonstrated antidepressant efficacy.
So the honest summary is that CBD may help some people with anxiety, for reasons that are not established, and there is no good evidence it treats depression. And the whole field has just been reviewed: a 2026 analysis in The Lancet Psychiatry pooled 54 placebo-controlled trials of CBD, THC, synthetic cannabinoids and whole-plant products. It found no significant benefit for anxiety or PTSD, and no eligible trial of cannabinoids as a primary treatment for depression at all. Some signals appeared for cannabis use disorder, insomnia, tics and autism, but the evidence was generally weak.
What about THC?
THC is a different case, because it changes mood immediately and obviously — that is why people use it. Its main intoxicating action is through the brain’s own CB1 cannabinoid receptors, a separate system, although it can influence serotonin signalling indirectly. Whether that mood change is a treatment is the question, and the answer so far is no. A 2019 review found very low quality evidence that pharmaceutical THC gave a small improvement in anxiety in people who had it alongside another illness, and no effect on depression. It also found THC-containing preparations made symptoms markedly worse in people with psychosis. And a separate 2020 analysis of laboratory studies found that a single dose of THC reliably produced anxiety, low mood and other psychiatric symptoms in healthy volunteers, with large effects.
Dose clearly matters: lower doses generally produce less anxiety than higher ones, and some users report relief at low doses. That is a reasonable argument for dose-sensitive trials. It is not evidence that THC treats an anxiety disorder or depression. For mood, the honest position on THC is the same as on CBD: real effects, no demonstrated treatment, and for THC an added risk of making the problem worse.
The part that matters more: taking CBD with antidepressants
The serotonin question becomes practical if you already take an SSRI or a similar antidepressant and are thinking about adding CBD. There are two separate issues.
The first is the one people worry about: too much serotonin. Combining drugs that raise serotonin can cause serotonin syndrome, which ranges from mild agitation and sweating to a medical emergency. CBD is not known to raise serotonin in the way established serotonergic medicines do, and we could not find a confirmed case of serotonin syndrome caused by CBD combined with an SSRI. It is not an established clinical risk.
The second issue is better established and more likely to affect you. CBD slows down liver enzymes involved in processing some antidepressants. The clearest human evidence concerns citalopram: in a 2026 study, CBD given at 5 mg per kg of body weight a day — a few hundred milligrams for most adults, well above a retail serving — increased total citalopram exposure by 43%. Escitalopram uses similar pathways. Evidence for a clinically significant interaction with sertraline is much thinner: one laboratory study found only minimal inhibition, while a single case report described a possible interaction in a genetically susceptible patient. Where it happens, the antidepressant builds up to higher levels than your prescriber intended, and side effects that were mild can become noticeable. Our guide to CBD drug interactions covers which medicines are affected. The short version: if you take an antidepressant, tell the person who prescribed it before you add CBD, and do not stop or change the antidepressant on your own.
What to take from this
“CBD works on serotonin” is a laboratory finding that has become a marketing claim. Involvement of the 5-HT1A receptor is biologically plausible and reasonably supported in animals, but it has not been demonstrated as the mechanism behind any benefit in people. Human research suggests that high-dose CBD may ease anxiety in some circumstances, while it has not been shown to treat depression. If someone says a retail CBD product will lift your mood by “boosting serotonin”, they are extrapolating from animal experiments, not describing an established effect in people.
Nothing in this article is medical advice. If you are struggling with low mood or anxiety, speak to a doctor. If you take antidepressants, do not add CBD without discussing it with your prescriber.
